| Document |
Document Title |
|
WO/2023/227069A1 |
The present invention relates to use of polidocanol with a single molecular weight in the preparation of a drug for treating disease. The polidocanol can serve as a curing agent and/or a hemostatic agent for treatment. The polidocanol wi...
|
|
WO/2023/223951A1 |
The present invention addresses the problem of providing a medicine for treating cardiovascular disease associated with inflammation of the cardiovascular system related to IL-6 and/or IL-1β. The present invention relates to an IL-6 and...
|
|
WO/2023/222040A1 |
The present invention relates to a recombinant erythropoietin, a nucleic acid molecule encoding same, a fusion protein comprising same, an expression vector, host cell and composition thereof, and an application thereof. The recombinant ...
|
|
WO/2023/223984A1 |
The present invention addresses the problem of providing a method for preserving platelets in a refrigerated or frozen state while retaining more functions of the platelets and to provide a platelet preservation solution, etc., for use i...
|
|
WO/2023/222770A1 |
The invention relates a novel isolated recombinant fibrinogen and to a eucaryotic cell producing said novel recombinant fibrinogen, as well as to a fibrin sealant and a fibrin sealant kit comprising the novel isolated recombinant fibrino...
|
|
WO/2023/221797A1 |
The present invention relates to a heterocyclic compound, a pharmaceutical composition comprising same, and a preparation method for the heterocyclic compound, and further relates to a use of the compound in the preparation of a drug for...
|
|
WO/2023/220739A1 |
Provided herein are methods for administering platelet derivatives, such as freeze-dried platelet derivatives (FDPDs) to a subject having Hermansky Pudlak Syndrome (HPS) and Bernard Soulier Syndrome (BSS), comprising administering an eff...
|
|
WO/2023/217077A1 |
Disclosed are a phenylpyrazole compound and an application thereof. The structure of the compound is as shown in general formula (I), and the definitions of the various substituents in the formula are given in the description. Also discl...
|
|
WO/2023/219378A1 |
The present invention relates to a pharmaceutical formulation composition for a plasma protein, particularly an ADAMTS-13 protein, and a composition for the prevention or treatment of thrombotic diseases, comprising same. The present inv...
|
|
WO/2023/220237A1 |
The present disclosure relates to benzothiazole compounds of formula (I) and to methods of using such compounds. The present disclosure further relates to the use of the compounds described herein, or pharmaceutical compositions thereof,...
|
|
WO/2023/219915A1 |
A subject can be treated for cardiogenic shock and/or sepsis, or their symptoms using platelet-derived extracellular vesicles (PEVs) or mitlets that include PEVS. The PEVs include mitochondria. The PEVs can be collected by obtaining bloo...
|
|
WO/2023/220636A1 |
Disclosed herein are methods of pre-conditioning a subject with sickle cell disease in advance of plerixa for therapy comprising administration of an inhibitor of the polymerization of hemoglobin S and optionally aspirin and a P-selectin...
|
|
WO/2023/216429A1 |
Disclosed are a lumbrukinase buccal adhesive tablet, a preparation method therefor and use thereof. The preparation method for the lumbrukinase buccal adhesive tablet comprises the following steps: dissolving 0.6-4 parts of a β-cyclodex...
|
|
WO/2023/217904A1 |
The inventors developed a new system to modify tropism of syncytins, envelope proteins, which can be used to functionalize particles such as virus particle or more particularly viral- like particles (VLPs), and used for gene transfer or ...
|
|
WO/2023/219379A1 |
The present invention relates to a pharmaceutical formulation composition for plasma proteins, specifically ADAMTS-13 protein, and a composition for preventing or treating thrombotic diseases comprising same. The present invention signif...
|
|
WO/2023/214713A1 |
Disclosed is applicability in novel uses of a DO3A-based material containing a gadolinium complex as an antithrombotic agent or a coagulant, on the basis of a discovery finding that the DO3A-based material containing the gadolinium compl...
|
|
WO/2023/215879A1 |
Modified Factor Xa polypeptides having functional activity and reduced affinity for apixaban are provided. Nucleic acids encoding the modified Factor Xa polypeptides and vectors and host cells including the nucleic acids are also provide...
|
|
WO/2023/215877A1 |
Described herein are compositions and methods for targeted erythroid-specific protein degradation. The compositions described comprise a binding domain for a erythroid protein of interest, e.g., BCL11A, and a binding domain for a erythro...
|
|
WO/2023/212810A1 |
The present disclosure provides a lipid nanoparticle comprising an siRNA molecule against ADAMTS13, the siRNA molecule containing modified or unmodified nucleotides. Further provided is an siRNA molecule against ADAMTS13, the siRNA molec...
|
|
WO/2023/214238A1 |
A direct sodium removal ("DSR") infusate regimen and methods of use are provided for removing sodium and reducing fluid overload in patients with severe renal dysfunction and/or heart failure, in which a patient has at least a first DSR ...
|
|
WO/2023/207889A1 |
The present invention provides a boric acid proteasome inhibitor compound represented by formula I and use thereof as a proteasome inhibitor.
|
|
WO/2023/210767A1 |
Provided is a new technology for a chemical ligation reaction of oligonucleotides. When 2'-fluoro-5'-amino-nucleic acid (2F-5N nucleic acid) having a fluorine atom at the 2'-positon of 5'-amino-nucleic acid (5N nucleic acid) is synthesiz...
|
|
WO/2023/211315A1 |
The present application relates to the fields of genetics, gene therapy, and molecular biology. More specifically, the present invention relates to a nucleic acid that encodes a fusion protein based on FVIII-BDD (B-domain deleted coagula...
|
|
WO/2023/208169A1 |
The present disclosure relates to an ionic liquid of a coagulation XIa inhibitor. Specifically, the present invention relates to an ionic liquid formed by a compound as represented by formula (I) and an amino acid. The ionic liquid discl...
|
|
WO/2023/210661A1 |
Provided are [0] extracellular vesicles that present at least one cytokine extramembranously; [1] extracellular vesicles that present at least one target factor extramembranously; or [2] extracellular vesicles that present at least one t...
|
|
WO/2023/210670A1 |
The purpose of the present invention is to remove, prior to administration, particles in a solution preparation filled in a syringe. The present invention provides an injection preparation in which a solution is filled in a syringe, wher...
|
|
WO/2023/208106A1 |
The present invention provides a compound represented by formula (I), or a prodrug, a tautomer, a stereoisomer, a solvate, an isotope derivative, or a pharmaceutically acceptable salt thereof. The compound of the present invention is a n...
|
|
WO/2023/212539A1 |
Factor VIII variants and methods of use thereof are disclosed.
|
|
WO/2023/210740A1 |
The present invention addresses the problem of providing a medicinal drug that can treat and/or prevent diseases linked to oxidative stress, by inhibiting the protein-protein interaction between Keap1 and Nrf2 to activate Nrf2. The prese...
|
|
WO/2023/208003A1 |
The disclosure provides Cas12i polypeptides, fusion proteins comprising such Cas12i polypeptides, CRISPR-Cas12i systems comprising such Cas12i polypeptides or fusion proteins, and methods of using the same.
|
|
WO/2023/211316A1 |
The present application relates to the fields of genetics, gene therapy, and molecular biology. More specifically, the present invention relates to a codon-optimized nucleic acid that encodes the FVIII-BDD (B-domain deleted coagulation f...
|
|
WO/2023/203197A1 |
Stroke is the second cause of death and the first cause of adult disability in industrialized countries. The goal of emergency therapy for acute ischemic stroke is prompt restoration of blood flow to regions of brain that are ischemic bu...
|
|
WO/2023/201575A1 |
The present invention relates to the technical field of injection gels, and in particular to an injection type hydrogel, a preparation method therefor, and use of the injection type hydrogel as a submucosal injection for endoscope adjuva...
|
|
WO/2023/203791A1 |
One purpose of the present disclosure is to provide a novel pharmaceutical composition, preferably a pharmaceutical composition capable of adsorbing a variety of disease-causing substances in vivo. A pharmaceutical composition that com...
|
|
WO/2023/204292A1 |
A compound represented by formula (1) [where: A is a heterocyclic ring; R1 and R2 are each independently hydrogen, an alkyl, an alkenyl, or an alkynyl; R3 is an alkyl, an alkenyl, or an alkynyl; L is an alkylene or is not present; X1 is ...
|
|
WO/2023/202383A1 |
Disclosed in the present invention are a tetrahydrothienopyridine deuterated derivative, a preparation method therefor, and pharmaceutical use thereof. The derivative can be used for preparing a medicament for the prevention or treatment...
|
|
WO/2023/205415A1 |
Provided are pharmaceutical compositions comprising a pharmaceutically acceptable carrier or diluent and a compound represented by Formula (I): or pharmaceutically acceptable salts thereof, which are useful for the activation of TFEB and...
|
|
WO/2023/204279A1 |
One of the objectives of the present disclosure is to provide a novel adsorbent material to be used for adsorbing a wider range of adsorbates in comparison with non-patent document 1. Another objective of the present disclosure is to pro...
|
|
WO/2023/204278A1 |
One purpose of the present disclosure is to provide a novel pharmaceutical composition, and preferably, to provide a pharmaceutical composition which makes it possible to adsorb various disease-causing substances inside an organism. A ...
|
|
WO/2023/198114A1 |
An ALK2 kinase inhibitor as represented by general formula (I), a pharmaceutical composition thereof, a preparation method therefor, and use of the ALK2 kinase inhibitor in preparing a drug for the prevention and/or treatment of indicati...
|
|
WO/2023/198704A1 |
The present invention provides a two-component drug delivery system for intravenous administration of an aqueous and sterile acetylsalicylic acid composition comprising: a first and second component which are physically separated, wherei...
|
|
WO/2023/198294A1 |
The invention provides a two-component drug delivery system for intravenous administration of an aqueous sterile acetylsalicylic acid composition comprising: a first and second components physically separated. The first component compris...
|
|
WO/2023/199345A1 |
The present invention relates to novel solid-state forms of Voxelotor of formula-1 and their preparation methods thereof. The Voxelotor of formula-1 is represented by the following structural formula. The present invention also related t...
|
|
WO/2023/199244A1 |
It is an object of the present invention a composition comprising N-acetylcysteine, or a pharmaceutically or food grade acceptable salt thereof or a derivative thereof, and a vitamin D, preferably vitamin D3 and/or vitamin D2, and prefer...
|
|
WO/2023/151653A9 |
An oleogel and a preparation method therefor and a use thereof. The oleogel comprises 60-90 wt% of liquid oil, 6-35 wt% of a structuring agent, and 4-15 wt% of water. The liquid oil comprises an unsaturated fatty acid, and the structurin...
|
|
WO/2023/198171A1 |
Provided are a novel coagulation factor X activating enzyme, a pharmaceutical composition comprising same, and use thereof in preparing a medicament for treating hemorrhage or hemorrhagic diseases. Also provided is a method for purifying...
|
|
WO/2023/199238A1 |
The present invention relates to novel compounds of the general formula (I) having the potential to treat cytokine related disorders, their tautomeric forms, their stereoisomers, their pharmaceutically acceptable salts, pharmaceutical co...
|
|
WO/2023/195535A1 |
The present invention provides: a stable fibrin clot-soluble protein excellent in production in protein-expressing cells in a serum-free medium and suppressing the production of impurities such as degradation products; a pharmaceutical f...
|
|
WO/2023/196506A1 |
The present invention is directed to various methods of for preventing and/or treating cardiovascular thrombosis, hereditary or acquired defects in platelet function, and hereditary or acquired thrombocytosis, wherein the method comprise...
|
|
WO/2023/195304A1 |
One purpose of the present invention is to provide an agent A that is for hemodialysis and that has excellent storage stability. This solid agent A for hemodialysis includes a granulated material containing a first sodium chloride, magne...
|
